Header and Body 2

Problem Addressed

To date, Sipuleucel-T is the only FDA approved cancer vaccine, which only provides a modest survival benefit in patients with prostate cancer. As an autologous cell-based vaccine, Sipuleucel-T and proposed therapies like it suffer from logistical difficulties that create barriers to its widespread adaptation. Conversely, more logistically feasible peptide-based cancer vaccines have low response rates. This technology is a generalizable strategy to improve the potency of peptide-based cancer vaccines